Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery

Drugs
Neil A ReynoldsLesley J Scott

Abstract

Fondaparinux sodium (Arixtra; fondaparinux) is the first of a new class of synthetic pentasaccharide anticoagulants that bind to antithrombin and inhibit the action of factor Xa. In three large, well designed trials, subcutaneous fondaparinux 2.5mg once daily was more effective than subcutaneous enoxaparin sodium (enoxaparin) 30 mg twice daily or 40 mg once daily at preventing venous thromboembolism (VTE) at day 11 in patients undergoing hip replacement, elective major knee or hip fracture surgery; a fourth trial demonstrated similar efficacy to enoxaparin 30 mg twice daily in hip replacement. Fondaparinux recipients had a lower incidence of proximal deep vein thrombosis (DVT) in two studies. In a meta-analysis of the four trials, patients receiving fondaparinux had a >50% reduction in the relative risk of VTE at day 11. Fondaparinux compared favourably with enoxaparin in several pharmacoeconomic analyses. In a large, controlled trial in hip fracture patients, extended prophylaxis with fondaparinux (duration 25-31 days) substantially reduced the incidence of VTE at day 25-32 compared with prophylaxis for 6-8 days, and was a cost-effective treatment strategy. Moreover, extended prophylaxis significantly decreased the rate of pro...Continue Reading

References

Jan 1, 1989·Annals of the New York Academy of Sciences·H L MessmoreJ Seghatchian
Jun 7, 2002·Lancet·Michael Rud LassenUNKNOWN European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee
Apr 16, 2003·Archives of Internal Medicine·Thomas M Hyers
Jun 11, 2003·Archives of Internal Medicine·Bengt I ErikssonUNKNOWN PENTasaccharide in HIp-FRActure Surgery Plus Investigators
Jul 2, 2003·The Journal of Biological Chemistry·Ericka M WiebeJeffrey I Weitz
Oct 31, 2003·The New England Journal of Medicine·H R BüllerUNKNOWN Matisse Investigators

❮ Previous
Next ❯

Citations

Nov 24, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Juan F Viles-GonzalezJuan J Badimon
Mar 2, 2006·Annals of Plastic Surgery·Thomas L ChungRonald P Silverman
Nov 30, 2006·Journal of Thrombosis and Thrombolysis·Apar Kishor GantiWilliam D Haire
Jun 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·William E Wade, William J Spruill
Sep 15, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Dean M Robinson, Keri Wellington
Apr 28, 2009·Clinical Nurse Specialist CNS·Patricia O'Malley
Jan 11, 2008·Drugs & Aging·Sohita Dhillon, Greg L Plosker
Dec 20, 2005·Journal of Thrombosis and Haemostasis : JTH·C PouplardY Gruel
Nov 2, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mia WolozinskyAlexander T Cohen
Jan 26, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Sean T Duggan
Mar 16, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Bruno Tribout, Florence Colin-Mercier
Feb 11, 2012·The Journal of Bone and Joint Surgery. British Volume·J T GriffithsJ D F Calder
Dec 5, 2017·The Cochrane Database of Systematic Reviews·Gustavo Ms BrandaoMarcone L Sobreira
Apr 22, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stephanie K A BlickLesley J Scott
Oct 21, 2011·Advances in Hematology·Ali ZalpourCarmen Escalante
Sep 18, 2016·Hematology/oncology Clinics of North America·Louis M Kwong, Jon A Kimball

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.